Vaxart Inc (VXRT) Stock Price, Quote & News

Company Profile

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influ...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 550 3500

Fax: 650 871 8580

Website: vaxart.com

Address:

170 Harbor Way, Suite 300, South San Francisco, United States

Elementary_Trader Feb. 24 at 12:45 AM

$VXRT There was supposed to be an ACIP Vaccine Committee meeting this week, but it was canceled without a reschedule date. Just interesting.

0 · Reply

Scootermn Feb. 24 at 12:13 AM

$VXRT It will be interesting to see what Vaxart presents at Oppenheimer on February 25th. Very interesting. If it's a clean, polished, norovirus-only presentation... I'm not disappointed. I'm not confused. I'm looking at a company that just confirmed — without saying a single word about it — that its most valuable program is under someone else's control. Stack it against everything we've tracked. Dynavax acquired. Altesa invested. $20 billion committed. BARDA aligned. mRNA defunded. RFK silent. Trading patterns compressed. And now... a premier public stage where the biggest story in biotech doesn't get mentioned? Every piece of evidence points in the same direction. And sometimes the most powerful confirmation isn't what someone says. It's the one thing they weren't allowed to. But if they walk out and lay cohort-400 data on the table? Then the uncomfortable questions start. Maybe the results weren't as strong as expected. Maybe negotiations with Sanofi stalled — or never existed. Maybe every data point, every connection, every thread was coincidence dressed up as a pattern. It happens. Sometimes the dots only connect because we want them to. Would that change anything? Would Sanofi still need an oral platform? Would the $20 billion commitment just disappear? Those are questions worth sitting with. So yes... it will be very interesting what they present. But it might be even more interesting what they don't. Because if norovirus is all we hear... the real presentation is happening somewhere we're not invited.

3 · Reply

ralm9 Feb. 24 at 12:11 AM

$VXRT typical move up before presentation. People are buying due to possible release of cohort datat being released before presentation in the 25th , if nothing new is presented this will drop again

2 · Reply

Grown_Up_Gambler Feb. 24 at 12:03 AM

$VXRT this guy does nothing but talk shit on X about Vaxart. In case anyone else wants to call him an idiot here's the link. He's probably on ST too, who knows 🤷. https://x.com/i/status/2026085125348282443

1 · Reply

jdog2020 Feb. 23 at 11:44 PM

$VXRT. I don’t think I’ve ever spoken about the intern. However I think he was more of a plant. He gave Lo a sense of our thinking just as a rat would. Then we beat the RS and Lo realized we were a force to be reckoned with. Lo had to change direction, a pivot of survival. After all, most biotech CEOs arent choir boys or girls but they are sharp operators and will do what it takes to survive. It wasn’t his first choice but the vaccine was coming whether he got his way or not. The pivot was a necessary business decision. My only concern is whether he has any more tricks up his sleeve but I’m thinking that ship may have sailed. Good luck to the stalwarts - It’s been a long time coming

1 · Reply

VXRTBULL Feb. 23 at 11:34 PM

$VXRT I made a few small buys today and noticed that they weren’t suppressing it at all. I think we are very close to a significant move. I still think it will be this week - Wednesday or Thursday.

0 · Reply

Vaxy_Tim Feb. 23 at 11:15 PM

$VXRT The people have spoken!! https://investors.vaxart.com/static-files/4e0b2ca4-099a-4d47-9568-f28733b0d4ea

1 · Reply

Tycho11261 Feb. 23 at 11:15 PM

$VXRT I can't help but check my account on a day like today. 8% doesn't sound like much, but when you've bought in the basement for a couple years...🔥🚀 Our time is here, ya'll. Enjoy the ride and HOLD EVERY VOTE. We're gonna need them🤘🤘🤘

0 · Reply

Jojosour Feb. 23 at 10:46 PM

$VXRT

0 · Reply

Raizor83 Feb. 23 at 10:43 PM

$VXRT that will do for today

0 · Reply

Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026

Nov 18, 2025, 9:28 PM EST - 3 months ago

Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript

Nov 13, 2025, 10:41 PM EST - 3 months ago

Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 8:00 AM EST - 3 months ago

Vaxart to Host Upcoming Conference Calls

Nov 5, 2025, 4:01 PM EST - 3 months ago

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

DVAX

Nov 5, 2025, 4:00 PM EST - 3 months ago

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

DVAX

Oct 8, 2025, 8:00 AM EDT - 4 months ago

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025

Sep 17, 2025, 4:05 PM EDT - 5 months ago

Vaxart Appoints W. Mark Watson as Lead Independent Director

Sep 10, 2025, 4:54 PM EDT - 5 months ago

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

Sep 10, 2025, 9:00 AM EDT - 5 months ago

Concerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special Meeting

Sep 8, 2025, 8:00 AM EDT - 6 months ago

Vaxart Announces Adjournment of Special Meeting of Stockholders

Sep 2, 2025, 4:30 PM EDT - 6 months ago

Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D.

Sep 2, 2025, 9:00 AM EDT - 6 months ago

Concerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board Accountability

Aug 21, 2025, 9:30 AM EDT - 6 months ago

Concerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder Rights

Aug 13, 2025, 9:01 PM EDT - 6 months ago

Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 5:25 PM EDT - 6 months ago

US orders Vaxart to stop COVID-19 trial amid mRNA wind down

Jul 24, 2025, 4:01 PM EDT - 7 months ago

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

Jun 13, 2025, 4:52 PM EDT - 9 months ago

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

Jun 11, 2025, 7:30 AM EDT - 9 months ago

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

Jun 10, 2025, 4:47 PM EDT - 9 months ago

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

Jun 2, 2025, 4:20 PM EDT - 9 months ago

Vaxart Announces Adjournment of Annual Meeting of Stockholders

May 29, 2025, 4:05 PM EDT - 9 months ago

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

May 29, 2025, 8:00 AM EDT - 9 months ago

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

May 28, 2025, 8:00 AM EDT - 9 months ago

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

May 27, 2025, 8:00 AM EDT - 9 months ago

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 20, 2025, 5:00 PM EDT - 9 months ago

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 16, 2025, 8:00 AM EDT - 10 months ago

Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting

May 15, 2025, 8:00 AM EDT - 10 months ago

Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 14, 2025, 4:05 PM EDT - 10 months ago

Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

May 13, 2025, 8:43 PM EDT - 10 months ago

Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 10 months ago

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 4:01 PM EDT - 10 months ago

Vaxart Appoints Jeroen Grasman as Chief Financial Officer

May 12, 2025, 8:00 AM EDT - 10 months ago

Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement

May 5, 2025, 8:00 AM EDT - 10 months ago

Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress

May 2, 2025, 8:00 AM EDT - 10 months ago

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

Apr 30, 2025, 8:00 AM EDT - 10 months ago

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

Apr 16, 2025, 8:00 AM EDT - 11 months ago

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

Apr 16, 2025, 8:00 AM EDT - 11 months ago

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

Mar 20, 2025, 6:25 PM EDT - 1 year ago

Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Mar 5, 2025, 4:05 PM EST - 1 year ago

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Jan 13, 2025, 7:55 PM EST - 1 year ago

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Dec 2, 2024, 4:01 PM EST - 1 year ago

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Nov 13, 2024, 6:19 PM EST - 1 year ago

Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:01 PM EST - 1 year ago

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Sep 30, 2024, 4:12 PM EDT - 1 year ago

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Aug 15, 2024, 1:57 PM EDT - 1 year ago

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

Aug 8, 2024, 8:51 PM EDT - 1 year ago

Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

Elementary_Trader Feb. 24 at 12:45 AM

$VXRT There was supposed to be an ACIP Vaccine Committee meeting this week, but it was canceled without a reschedule date. Just interesting.

0 · Reply

Scootermn Feb. 24 at 12:13 AM

3 · Reply

ralm9 Feb. 24 at 12:11 AM

$VXRT typical move up before presentation. People are buying due to possible release of cohort datat being released before presentation in the 25th , if nothing new is presented this will drop again

2 · Reply

Grown_Up_Gambler Feb. 24 at 12:03 AM

1 · Reply

jdog2020 Feb. 23 at 11:44 PM

1 · Reply

VXRTBULL Feb. 23 at 11:34 PM

$VXRT I made a few small buys today and noticed that they weren’t suppressing it at all. I think we are very close to a significant move. I still think it will be this week - Wednesday or Thursday.

0 · Reply

Vaxy_Tim Feb. 23 at 11:15 PM

$VXRT The people have spoken!! https://investors.vaxart.com/static-files/4e0b2ca4-099a-4d47-9568-f28733b0d4ea

1 · Reply

Tycho11261 Feb. 23 at 11:15 PM

0 · Reply

Jojosour Feb. 23 at 10:46 PM

$VXRT

0 · Reply

Raizor83 Feb. 23 at 10:43 PM

$VXRT that will do for today

0 · Reply

TahoeandChief Feb. 23 at 10:26 PM

$VXRT I’m worried about T-cells

1 · Reply

WALTERPAYTON34 Feb. 23 at 10:20 PM

$VXRT let’s slow walk up to the 70s and then boom Massive volume

0 · Reply

WALTERPAYTON34 Feb. 23 at 10:14 PM

$VXRT there you go Up up and away @Vaxylove @BGirl

0 · Reply

WALTERPAYTON34 Feb. 23 at 10:13 PM

$VXRT I’m put a buy in for an island in the Caribbean I can pay cash soon

1 · Reply

Niraj3939 Feb. 23 at 10:10 PM

$VXRT Most of people talks about partnerships and dreaming about sky rocket SP. Let first 400 result positive. We don't know whether anyone really interested in buyout.

1 · Reply

Kher33 Feb. 23 at 10:06 PM

$VXRT

0 · Reply

Robertwll Feb. 23 at 10:03 PM

$VXRT seems to me that Sanofi wouldn’t be excited for us to go to this conference if it’s focused on investing. How would you say it… do they really want us to put out our shingle at the exact place for the exact people that ought to be wanting our platform right now?

1 · Reply

Joe_Mussia Feb. 23 at 10:01 PM

$VXRT Tomorrow will be like: "Nuthin'"

2 · Reply

GOGOVAXY Feb. 23 at 9:57 PM

$VXRT Tomorrow, February 24-26, 2026, the Global Life Science Partnering & Investor Conference 2026, organized by Biocom California, begins in La Jolla (a suburb of San Diego, California). This conference is considered one of the most prestigious dealmaking events of the year in the biotech sector. Key Event Details: Format: This is not a scientific convention, but a platform for investment negotiations and partnerships. Attendees: Over 500 investors and senior executives (CEOs, heads of business development) from 20 countries. Confirmed giants seeking acquisitions include AbbVie, Amgen, Eli Lilly, and Pfizer. Main Activity: Over 1,000 closed one-on-one meetings to discuss licensing, financing, and strategic collaborations https://www.biocom.org/conferences/global-partnering-conference/

3 · Reply

TahoeandChief Feb. 23 at 9:53 PM

$VXRT next stop $6.30

1 · Reply

How2TieAKnot Feb. 23 at 9:34 PM

$VXRT Anyone know of a pending COVID study (new, I'm waiting for more info via Iowa Accellacare.)

2 · Reply

Vaxy_Tim Feb. 23 at 9:28 PM

$VXRT Slides are fire!🔥 https://investors.vaxart.com/static-files/c67e59e1-3e25-4354-a605-db6cfb113a0a

3 · Reply

Market Cap	97.49M
Revenue (ttm)	28.70M
Net Income (ttm)	-66.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-233.28%
Debt to Equity Ratio	0.00

Volume	11,568,300
Avg Vol	5,416,006
Day's Range	N/A - N/A
Shares Out	228.31M
Stochastic %K	7%
Beta	1.14
Analysts	Strong Sell
Price Target	$4.67